Adakitug

DB05484InvestigationalSmall molecule

MDX-018, also known as HuMax-Inflam, is a fully human antibody that is directed to IL-8 (interleukin-8) and may have potential application in oncology and inflammation. Trials will initially focus on... Trials will initially focus on studies to treat glioblastoma, a cancer of the central nervous system.

Mechanism: he drug inhibits tumour growth by targetting interleukin-8 (IL-8), a major inflammation mediator.
Curator reviewed
Primary indication: Investigated for use/treatment in autoimmune diseases and inflammatory disorders (unspecified).Curator reviewed
Also known as: HuMax IL-8 · HuMax-IL-8 · HuMax-IL8
Code names: BMS-986253 · MDX-018

Resolves to

Compound

UNIIN0YWS8X3S9

Targets

P10145CXCL8

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Adakitug, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account